Logo Istituto Affiliato

Institute of Oncology Research (IOR),

affiliated to USI,

run by an


foundation with the same name


Publications - Prostate Cancer Biology Lab


Relevant publications

  • Temilola DO, Wium M, Paccez J, Salukazana AS, Otu HH, Carbone GM, Kaestner L, Cacciatore S and Zerbini LF. Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population. Cancers (Basel) (2023) 15.  https://www.ncbi.nlm.nih.gov/pubmed/37568783.
  • Suri GS, Kaur G, Carbone GM and Shinde D. Metabolomics in oncology. Cancer Rep (Hoboken) (2023) 6, e1795.  https://www.ncbi.nlm.nih.gov/pubmed/36811317.
  • Cacciatore A, Albino D, Catapano CV and Carbone GM. Preclinical Models of Neuroendocrine Prostate Cancer. Curr Protoc (2023) 3, e742.  https://www.ncbi.nlm.nih.gov/pubmed/37166213.
  • Zoma M, Curti L, Shinde D, Albino D, Mitra A, Sgrignani J, Mapelli SN, Sandrini G, Civenni G, Merulla J, Chiorino G, Kunderfranco P, Cacciatore A, Kokanovic A, Rinaldi A, Cavalli A, Catapano CV and Carbone GM. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nat Commun (2021) 12, 4147.  https://www.ncbi.nlm.nih.gov/pubmed/34230470.
  • Albino D, Falcione M, Uboldi V, Temilola DO, Sandrini G, Merulla J, Civenni G, Kokanovic A, Sturchler A, Shinde D, Garofalo M, Mestre RP, Constancio V, Wium M, Burrello J, Baranzini N, Grimaldi A, Theurillat JP, Bossi D, Barile L, Henrique RM, Jeronimo C, Zerbini LF, Catapano CV and Carbone GM. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Commun Biol (2021) 4, 119.  https://www.ncbi.nlm.nih.gov/pubmed/33500545.
  • Mapelli SN, Albino D, Mello-Grand M, Shinde D, Scimeca M, Bonfiglio R, Bonanno E, Chiorino G, Garcia-Escudero R, Catapano CV and Carbone GM. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers (Basel) (2020) 12.  https://www.ncbi.nlm.nih.gov/pubmed/31936761.
  • Shinde D, Albino D, Zoma M, Mutti A, Mapelli SN, Civenni G, Kokanovic A, Merulla J, Perez-Escuredo J, Costales P, Moris F, Catapano CV and Carbone GM. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer. Eur Urol Oncol (2019) 2, 415-424.  https://www.ncbi.nlm.nih.gov/pubmed/31277777.
  • Mapelli SN, Napoli S, Pisignano G, Garcia-Escudero R, Carbone GM and Catapano CV. Deciphering the complexity of human non-coding promoter-proximal transcriptome. Bioinformatics (2019) 35, 2529-2534.  https://www.ncbi.nlm.nih.gov/pubmed/30535182.
  • Civenni G, Carbone GM and Catapano CV. Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery. Curr Protoc Pharmacol (2018) 81, e39.  https://pubmed.ncbi.nlm.nih.gov/29927081/.
  • Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV and Carbone GM. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. J Clin Invest (2016) 126, 4585-4602.  https://pubmed.ncbi.nlm.nih.gov/27820701/.
  • Albino D, Civenni G, Dallavalle C, Roos M, Jahns H, Curti L, Rossi S, Pinton S, D'Ambrosio G, Sessa F, Hall J, Catapano CV and Carbone GM. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer. Cancer Res (2016) 76, 3629-3643.  https://www.ncbi.nlm.nih.gov/pubmed/27197175. 
  • Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, Sessa F, Garcia-Escudero R, Thalmann GN, Chiorino G, Catapano CV and Carbone GM. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression. Cancer Res (2013) 73, 4533-4547.  https://www.ncbi.nlm.nih.gov/pubmed/23687337.
  • Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV and Carbone GM. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res (2012) 72, 2889-2900.  https://www.ncbi.nlm.nih.gov/pubmed/22505649.
  • Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV and Carbone GM. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 5, e10547.  https://www.ncbi.nlm.nih.gov/pubmed/20479932.
  • Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV and Carbone GM. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. Oncogene (2008) 27, 2877-2885.  https://www.ncbi.nlm.nih.gov/pubmed/18037958.
  • Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM and Bonapace IM. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene (2012) 31, 4878-4887.  https://pubmed.ncbi.nlm.nih.gov/22330138/.

Collapse all